Salt Lake City, UT, United States
Salt Lake City, UT, United States

Time filter

Source Type

Heilman K.M.,Myriad Pharmaceuticals Inc.
CONTINUUM Lifelong Learning in Neurology | Year: 2010

Humans need to perform skilled movements to successfully interact with their environment as well as take care of themselves and others. These important skilled purposeful actions are primarily performed by the forelimb, and the loss of these skills is called apraxia. This review describes the means of testing, the pathophysiology, and the clinical characteristics that define five different general forms of forelimb apraxia including: (1) ideational apraxia, an inability to correctly sequence a series of acts leading to a goal; (2) conceptual apraxia, a loss of mechanical tool knowledge; (3) ideomotor apraxia, a loss of the knowledge of how when making transitive and intransitive movements to correctly posture and move the forelimb in space; (4) dissociation apraxia, a modality-specific deficit in eliciting learned skilled acts; and (5) limb-kinetic apraxia, a loss of hand-finger deftness. Copyright © 2010, American Academy of Neurology.


Patent
Myriad Pharmaceuticals Inc. | Date: 2010-03-25

The present application discloses and claims liquid pharmaceutical compositions comprising bevirimat dimeglumine as a drug substance, methods of treatment comprising administering such compositions to a subject in need thereof, and the use of such compositions in the manufacture of medicaments.


Patent
Myriad Pharmaceuticals Inc. | Date: 2010-05-06

Novel pyrrole derivatives are disclosed as A_(42)-lowering agents for the treatment and prevention of neurodegenerative disorders characterized by the formation or accumulation of amyloid plaques comprising the A_(42 )peptide.


Patent
Myriad Pharmaceuticals Inc. | Date: 2010-06-04

The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.


Patent
Myriad Pharmaceuticals Inc. | Date: 2010-04-30

The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient.


Patent
Myriad Pharmaceuticals Inc. | Date: 2010-02-16

A method of treating non-small cell lung cancer (NSCLC), and especially NSCLC that has metastasized to brain is disclosed.


Patent
Myriad Pharmaceuticals Inc. | Date: 2010-03-08

The invention provides novel compounds useful for the treatment of neurodegenerative disorders including Alzheimers disease and dementia. The compounds have a substituents chosen from -L-C(O)OH, -L-CHCHC(O)OH, -L-C(O)NH_(2), -L-C(0)NH(C_(1-3)alkyl), -L-C(O)N(C_(1-3)alkyl)_(2), -L-S(O)_(2)(C_(1-3)alkyl), -L-S(O)_(2)NH_(2), -L-S(O)_(2)N(C_(1-3)alkyl)_(2), -L-S(O)_(2)NH(C_(1-3)alkyl), -L-C(O)NHOH, -L-C(O)CH_(2)NH_(2), -L-C(O)CH_(2)OH, -L-C(O)CH_(2)SH, -L-C(O)NHCN, -L-NHC(O)OR_(o), -L-C(O)NHR_(o), -L-NH(CO)NHR_(o), -L-C(O)N(R_(o))_(2), -L-NH(CO)N(R_(o))_(2), -L-sulfo, -L-(2,6 difluorophenol), -L-phosphono, and -L-tetrazolyl, where L is a linker.


Patent
Myriad Pharmaceuticals Inc. | Date: 2010-05-14

The invention provides novel therapeutic compounds, pharmaceutical compositions comprising these compounds, and methods for using these compounds and compositions to treat diseases and disorders, such as cancer.


News Article | July 12, 2010
Site: www.xconomy.com

After the Meltdown: Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area’s highest-profile clinical trial failures of 2009. And a big part of the Lexington, MA-based company’s recovery has been to learn from the failure and advance other drug candidates in its pipeline. After Synta (NASDAQ:SNTA) halted its pivotal trial of the drug elesclomol for patients with a deadly form of skin cancer in February 2009, the firm saw its common stock value fall more than 80 percent in a day. The company cut 41 percent of its staff, and then lost the London drug giant GlaxoSmithKline as its partner in commercializing the cancer drug last June. However, there were several reasons during that time to think the firm still had good prospects, Safi Bahcall, Synta’s chief executive, says. The company still had a couple years worth of cash in the bank, more drugs in its pipeline, and an understanding that many biotechs hit bumps along the road to success. The company is now holding onto the promise of its mid-stage cancer drug, STA-9090, which Bahcall says has supplanted elesclomol as the top drug candidate in the firm’s pipeline. Plus, he’s aware of at least a few other biotech companies such as Seattle-based Dendreon that have brought drugs to market after setbacks on par with the one Synta suffered last year. “If you look at essentially every good company, and essentially every good drug, they all had a setback,” Bahcall says. To make his point, he cites Dendreon, which got FDA approval for its immune booster drug for prostate cancer in April after 18 years in business. Synta hasn’t lost hope for elesclomol. The company stopped its late-stage trial of the drug last year because there were … Next Page »

Loading Myriad Pharmaceuticals Inc. collaborators
Loading Myriad Pharmaceuticals Inc. collaborators